ReviewBiomedicines2023
HIV-HBV Coinfection-Current Challenges for Virologic Monitoring.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- High Burden of Occult Hepatitis B Infection in HIV-Infected Patients in Southern Vietnam: Insights from Serological and Molecular Analysis.International journal of molecular sciences · 2026Article
- Managing HBV/HIV coinfection: from diagnostics to long-acting antiretroviral therapy.Clinical and experimental hepatology · 2026Review
- Acceptability of HBV, HCV, and HIV screening among injured patients presenting to the adult emergency department in Blantyre, Malawi.BMC infectious diseases · 2026Article
- Retention in care and viral suppression in people living with HIV and chronic hepatitis B in Maputo City, Mozambique: a prospective cohort study.Scientific reports · 2026Article
- Hepatic Viral Reservoirs in Concurrent HIV and HBV: From Mechanistic Insight to Integrated Cure Strategies.Infection and drug resistance · 2026Review
- HIV and Hepatitis B co-infection in Tanzania: Analysis of the 2022-2023 Tanzania HIV Impact Survey.PloS one · 2026Article
- Triple Burden of HIV, HBV and HDV in Adults with Childhood Parenterally Acquired Infections: A Romanian Single-Center Study.Pathogens (Basel, Switzerland) · 2025Article
- Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States.Infectious diseases and therapy · 2025Article
- Hepatitis B virus exposure among adolescents living with HIV: a cross-sectional study of samples referred to the national viral load and early infant diagnosis reference laboratory in Uganda.BMC infectious diseases · 2025Article
- HIV/AIDS and HBV co-infection with optimal control strategies and cost-effectiveness analyses using integer order model.Scientific reports · 2025Article
- Evaluating the Efficacy of Repurposed Antiretrovirals in Hepatitis B Virus Treatment: A Narrative Review of the Pros and Cons.International journal of molecular sciences · 2025Review
- FibroScanMicroorganisms · 2024Article
- A dynamical optimal control theory and cost-effectiveness analyses of the HBV and HIV/AIDS co-infection model.Frontiers in public health · 2024Article
- Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients-A Cohort from the North-Eastern Part of Romania.Microorganisms · 2023Article
- Epidemiology of hepatitis B, hepatitis C, and syphilis co-infections in HIV-1 patients: a retrospective cross-sectional study of prevalence and viral load correlates.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV-HBV coinfected patients have higher rates of liver-related morbidity, hospitalizations, and mortality compared to HBV or HIV mono-infected ones. Clinical studies have shown an accelerated progression of liver fibrosis and an increased incidence of HCC, resulting from the combined action of HBV replication, immune-mediated hepatocytolysis, and HIV-induced immunosuppression and immunosenescence. Antiviral therapy based on dually active antiretrovirals is highly efficient, but late initiation, global disparities in accessibility, suboptimal regimens, and adherence issues may limit its impact on the development of end-stage liver disease. In this paper, we review the mechanisms of liver injuries in HIV-HBV coinfected patients and the novel biomarkers that can be used for treatment monitoring in HIV-HBV coinfected persons: markers that assess viral suppression, markers for liver fibrosis evaluation, and predictors of oncogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.